This webinar will discuss how to classify HPAPIs in early development and share recommendations for safe...
| This week's Fierce LifeSci is brought to you by Catalent.
Trouble viewing? Click here.
|
| | Tuesday, October 12, 2021 | 11am ET / 8am PT | |
|
|
| | | Small molecule drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs), particularly in areas such as oncology. Development of HPAPIs presents unique challenges for product containment and requires special consideration in equipment selection, operating procedures, and safety processes. This webinar will discuss how to classify HPAPIs in early development and share recommendations for safe product handling, from clinical manufacturing to commercialization. The speakers will also share the key advantages of using micronization technology for the development and manufacturing of HPAPIs. |
|---|
| |
|
|
| | | Key Learning Objectives: Understand the key data points required for evaluating and classifying highly potent APIs Review associated occupational exposure limits and handling recommendations Gain insight into the benefits of HPAPI manufacturing using micronization Learn about facility set up, engineering controls and how to incorporate flexibility in manufacturing various batch sizes Considerations in selecting a partner with robust expertise in micronizing HPAPIs |
|---|
| |
|
|
| | You are currently subscribed as [email protected]
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. | |
|
|
